Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock a Multicenter, Randomized Controled Trial.
Led by Centre Hospitalier de Bethune · Updated on 2026-10-27
65
Participants Needed
14
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Among patients admitted after an out-of-hospital cardiac arrest (OHCA) in intensive care unit (ICU), almost two thirds of patients will develop in the first hours a post-cardiac arrest (CA) shock. This post-CA shock, combines cardiac and hemodynamic failure, generally resulting in multi-organ failure and early death in up to 35% of patients. Experimental data suggest that intravenous ascorbic acid (vitamin C) may attenuate inflammation and vascular injury related to sepsis or surgery. Preclinical and clinical studies also provide safety data of high dose intravenous vitamin C (\> 200mg/kg/day) with no significant adverse event reported and favorable impact on outcome. Experimental data also suggest beneficial effect of vitamin C in post-CA management with improvement of shock and multi-organ failure with potential benefit on neuroprotection and outcome.
The study is a phase II multicenter prospective controlled open-label trial randomized in two parallel groups :
* Expérimental group: Standard of care care for post-CA shock + Vitamin C (Vit-C) 200mg/kg/d IV (started as early as possible, no later than 1 h after randomization + thiamin (Vit B1) 200mg every 12 h during 3 days.
* Control group: Standard of care care for post CA shock according international guidelines.
Patient number to be enrolled : 234, Study duration :24 months and 28 days, Inclusion duration : 24 months, Patient participation : duration : 28 days
CONDITIONS
Brief Title
Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Collaborating Sponsor
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
Inclusion Criteria:
patients still comatose (Glasgow coma scale < 8) after an OHCA of presumed cardiac origin with ROSC < 60 min;
and treated with a norepinephrin or an epinephrin continuous infusion during at least 30 min before randomization to maintain mean arterial pressure (MAP) ≥ 65 mmHg.
Exclusion Criteria:
patients still comatose (Glasgow coma scale < 8) after an OHCA of presumed cardiac origin with ROSC < 60 min;
and treated with a norepinephrin or an epinephrin continuous infusion ≥ 0.2µg/kg/h, within 4 hours after OHCA, during at least 30 min/h to maintain mean arterial pressure (MAP) ≥ 65 mmHg.
Exclusion criteria:
minor or pregnant women;
OHCA from evident extracardiac cause (trauma, bleeding, poisoning, etc.);
interval between RACS and randomization > 6 hours;
extracorporeal circulatory assistance requirement in the first 4 hours after OHCA;
history of urolithiasis, oxalate nephropathy or hemochromatosis;
patients already treated with vit-C; known vit-C deficit;
inclusion in another study;
pre-existent severe chronic kidney disease (glomerular filtration rate < 30ml/min);
treatment limitationsor moribound
Patient with derpived freedom or with legal protective measures.
Patient not covered by French national health insurance
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating Accuracy of FloPatch FP120 Doppler Ultrasound Compared to Manual Pulse Checks in Cardiac Arrest Patients
Study of Willem17 AI Software for ECG Analysis in Patients With High-Risk Cardiac Conditions
Monitoring Brain Blood Flow and Cerebral Autoregulation in Critically Ill Children Using Transcranial Doppler A Prospective Observational Study
Brain and Heart Interactions in Comatose Patients After Cardiac Arrest
Ancillary Study of the HEAVENwARd Trial
Study of Butylphthalide to Improve Brain Function After Cardiac Arrest in Adults Aged 18 to 80
Randomized, Double-Blind, Placebo-Controlled Trial
Trial of a Combined Device Approach to Improve Survival After Out-of-Hospital Cardiac Arrest
China Registry Study on Extracorporeal Membrane Oxygenation ECMO Support for Heart and Lung Failure Patients
Using Advanced Brain MRI Scans to Predict Neurological Recovery in Coma Patients After Cardiac Arrest
Evaluation and Comparison of Early Brain Damage Scoring Systems at ICU Admission Following Cardiac Arrest
Comparing Survival After Two Types of Bystander CPR in Out-of-Hospital Cardiac Arrest
Chest Compression Only CPR Versus Standard CPR With Rescue Breaths
A Randomized Study of Trained Bystanders
Early intravenous high-dose vitamin C in postcardiac arrest shock (VICEPAC): study protocol for a randomised, single-blind, open-label, multicentre, controlled trial.